09921880

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX,

09921880

ENERGY, INSPEC
NEWS 43 Feb 13 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:12:01 ON 17 MAR 2003

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'BIOSIS' ENTERED AT 14:12:28 ON 17 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 14:12:28 ON 17 MAR 2003

FILE 'CAPLUS' ENTERED AT 14:12:28 ON 17 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:12:28 ON 17 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:12:28 ON 17 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

=> s adrenomedullin
L1 6835 ADRENOMEDULLIN

=> s l1 and (bladder or urination or urinate)
L2 20 L1 AND (BLADDER OR URINATION OR URINATE)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 11 DUP REM L2 (9 DUPLICATES REMOVED)

=> d l3 bib hit 1-11

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS
AN 2002:964607 CAPLUS
DN 138:23176
TI Method for gene expression profiling and kit for determining origin of tumors
IN Su, Andrew I.; Hampton, Garret M.
PA IRM LLC, Bermuda
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002101357	A2	20021219	WO 2002-US18628	20020610

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-297277P P 20010610
IT **Bladder**
Esophagus
Mammary gland
Prostate gland
(neoplasm; method for gene expression profiling and kit for detg. origin of tumors)
IT 9000-83-3, ATPase 9001-26-7, Blood-coagulation factor II 9001-62-1 9001-84-7, Phospholipase A2 9007-92-5, Glucagon, biological studies 9023-55-6, GMP synthetase 9026-00-0, Bile salt-stimulated lipase 9028-06-2, Proline 4-hydroxylase 9029-73-6, Phenylalanine hydroxylase 9030-22-2, Uridine phosphorylase 9031-86-1, Aspartoacylase 9032-25-1, Cytochrome b5 reductase 9036-09-3, Chymotrypsin C 9074-83-3, Glutamyl aminopeptidase 11075-17-5, Carboxypeptidase A1 37228-64-1, Acid .beta.-glucosidase 39346-44-6 80295-53-0, Complement C5 83268-44-4 91386-47-9, Trypsin-2 104200-25-1, Cystatin A 141467-21-2, Calcium/calmodulin-dependent protein kinase I 142008-29-5, Protein kinase A 151662-26-9, Interleukin 2-inducible T-cell kinase 153967-26-1, Carboxypeptidase D 154835-90-2, **Adrenomedullin** 181186-98-1, Carboxypeptidase A2 182762-08-9, Caspase 4 193829-96-8, Cortistatin 194368-66-6, Angiopoietin 2 199877-12-8, Protein kinase PCTAIRE-3 352031-63-1, Fibroblast activation protein .alpha. 362607-76-9, Kallikrein 2
RL: ANT (Analyte); BSU (Biological study, unclassified); DEV (Device component use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(method for gene expression profiling and kit for detg. origin of tumors)

Q9921880

L3 ANSWER 2 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2003:120839 BIOSIS
DN PREV200300120839
TI Zoophysiology. Endocrines and osmoregulation: A comparative account in vertebrates, Second edition.
AU Bentley, Peter J. (1)
CS (1) Department of Physiology, University of Western Australia, Nedlands, WA, 6907, Australia Australia
SO Bentley, Peter J.. Zoophysiology, (2002) Vol. 39, No. 0, pp. i-xvi, 1-292. Zoophysiology. Endocrines and osmoregulation: A comparative account in vertebrates, Second edition. print.
Publisher: Springer-Verlag GmbH & Co. KG Heidelberger Platz 3, D-14197, Berlin, Germany.
ISSN: 0720-1842. ISBN: 3-540-42683-3 (cloth).
DT Book
LA English
IT Major Concepts
Biochemistry and Molecular Biophysics; Endocrine System (Chemical Coordination and Homeostasis)
IT Parts, Structures, & Systems of Organisms
capillaries: circulatory system; cell membrane; cloaca: embryonic structure, excretory system; colon: digestive system; endocrine glands: endocrine system; endocrine system: endocrine system; gills: respiratory system; gut: digestive system; hypothalamus: nervous system; kidney: excretory system; neurohypophysis: nervous system; pituitary gland: endocrine system; respiratory tract: respiratory system; salt glands; skin: integumentary system; sweat glands: integumentary system; urinary **bladder**: excretory system
IT Chemicals & Biochemicals
adrenaline [epinephrine]; adrenocorticosteroids; **adrenomedullin**; angiotensin; catecholamines; growth hormone; guanylin peptides; hormone receptors; mineralocorticoid hormones; natriuretic peptide hormones; nitrogen: metabolism; noradrenaline [norepinephrine]; prolactin; renin; salts; thyroid hormones; urotensins; vasopressin; vasotocin
RN 51-43-4 (ADRENALINE)
51-43-4 (EPINEPHRINE)
154835-90-2 (**ADRENOMEDULLIN**)
1407-47-2 (ANGIOTENSIN)
9002-72-6 (GROWTH HORMONE)
7727-37-9 (NITROGEN)
51-41-2 (NORADRENALINE)
51-41-2 (NOREPINEPHRINE)
9002-62-4 (PROLACTIN)
9015-94-5 (RENIN)
7647-14-5 (SALTS)
12651-34-2 (UROTENSINS)
11000-17-2 (VASOPRESSIN)
9034-50-8 (VASOTOCIN)

L3 ANSWER 3 OF 11 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2002334425 EMBASE
TI Urinary tract infections in small animals: Pathophysiology and diagnosis.
AU Dunning M.; Stonehewer J.
SO In Practice, (2002) 24/8 (418-432).
Refs: 22
ISSN: 0263-841X CODEN: IPRCDH
CY United Kingdom
DT Journal; Article

09921880

FS 004 Microbiology
005 General Pathology and Pathological Anatomy
028 Urology and Nephrology
037 Drug Literature Index
LA English
SL English
CT Medical Descriptors:
*urinary tract infection: CO, complication
*urinary tract infection: DI, diagnosis
*urinary tract infection: DT, drug therapy
*urinary tract infection: ET, etiology
dog
cat
pathophysiology
diagnostic approach route
treatment planning
long term care
Gram positive bacterium
clinical feature
echography
urinalysis
bladder catheterization
urine culture
antimicrobial therapy
nonhuman
male
female
controlled study
article
Drug Descriptors:
glycosaminoglycan: EC, endogenous compound
ammonia: EC, endogenous compound
immunoglobulin A: EC, endogenous compound
immunoglobulin G: EC, endogenous compound
immunoglobulin M: EC, endogenous compound
carboxylic acid derivative: EC, endogenous compound
dicarboxylic acid derivative: EC, endogenous compound
aromatic carboxylic acid: EC, endogenous compound
adrenomedullin: EC, endogenous compound
glucocorticoid
antiinfective agent: DT, drug therapy
RN (ammonia) 14798-03-9, 51847-23-5, 7664-41-7; (immunoglobulin G) 97794-27-9; (immunoglobulin M) 9007-85-6; (**adrenomedullin**) 148498-78-6

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS
AN 2001:186032 CAPLUS
DN 134:217592
TI Determination of AM-binding proteins and the association of **adrenomedullin** (AM) therewith
IN Cuttitta, Frank; Elsasser, Ted H.; Martinez, Alfredo; Pio, Ruben
PA Government of the United States of America as Represented by the Secretary, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

09921880

PI WO 2001018550 A2 20010315 WO 2000-US24722 20000908
WO 2001018550 C2 20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2000073622 A5 20010410 AU 2000-73622 20000908
EP 1214600 A2 20020619 EP 2000-961705 20000908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
PRAI US 1999-153397P P 19990910
WO 2000-US24722 W 20000908

TI Determination of AM-binding proteins and the association of **adrenomedullin** (AM) therewith

AB The present invention provides methods for the isolation, identification, and purifn. of **adrenomedullin** (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders assocd. with abnormally elevated AM levels. In addn., the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/fH complexes, and antibodies specifically reactive with these complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compns. comprising these antibodies. The present invention addnl. provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents.

ST **adrenomedullin** detn antibody diabetes cancer treatment

IT Animal tissue
Antidiabetic agents
Antitumor agents
Blood analysis
(**adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Brain, neoplasm
Cirrhosis
Heart, disease
Inflammation
Kidney, neoplasm
Liver, neoplasm
Lung, disease
Lung, neoplasm
Ovary, neoplasm
Sepsis
Skin, neoplasm
Stomach, neoplasm
(**adrenomedullin** and **adrenomedullin**-binding protein detn. in blood and tissues in diseases)

IT Diabetes mellitus

(**adrenomedullin** of blood in diabetes)
IT Neoplasm
(**adrenomedullin** of blood in neoplasia)
IT Antitumor agents
(**bladder**; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Antitumor agents
(brain; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Uterus, neoplasm
(cervix, inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT Antitumor agents
(cervix; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Uterus, neoplasm
(cervix; **adrenomedullin** and **adrenomedullin**-binding
protein detn. in blood and tissues in diseases)
IT Intestine, neoplasm
(colon, inhibitors; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Antitumor agents
(colon; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Intestine, neoplasm
(colon; **adrenomedullin** and **adrenomedullin**-binding
protein detn. in blood and tissues in diseases)
IT Uterus, neoplasm
(endometrium, inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT Antitumor agents
(endometrium; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Uterus, neoplasm
(endometrium; **adrenomedullin** and **adrenomedullin**
-binding protein detn. in blood and tissues in diseases)
IT Antitumor agents
(esophagus; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Antitumor agents
(gallbladder tumor inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT Liver, neoplasm
(hepatoma, inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT Antitumor agents
(hepatoma; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)

09921880

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; factor H detection as **adrenomedullin**-binding protein AMBP-1)

IT Brain, neoplasm
Kidney, neoplasm
Lung, neoplasm
Ovary, neoplasm
Pheochromocytoma
Skin, neoplasm
Stomach, neoplasm
(inhibitors; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Antitumor agents
(kidney; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Antitumor agents
(lung; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Animal cell
(lysate; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Antibodies
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT **Bladder**
Esophagus
Prostate gland
Urethra
(neoplasm, inhibitors; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT **Bladder**
Esophagus
Gallbladder
Prostate gland
Salivary gland
Urethra
Vagina
(neoplasm; **adrenomedullin** and **adrenomedullin**-binding protein detn. in blood and tissues in diseases)

IT Antitumor agents
(ovary; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Antitumor agents
(prostate gland; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Immunoassay
(radioimmunoassay; **adrenomedullin** and **adrenomedullin**-binding protein detn. and antibodies utilization therein and treatment of cancer and diabetes therewith)

IT Intestine, neoplasm
(rectum, carcinoma; **adrenomedullin** and **adrenomedullin**
-binding protein detn. in blood and tissues in diseases)
IT Intestine, neoplasm
(rectum, inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT Antitumor agents
(rectum; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Antitumor agents
(salivary gland; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Antitumor agents
(skin; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Antitumor agents
(small intestine; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Intestine, neoplasm
(small, inhibitors; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Intestine, neoplasm
(small; **adrenomedullin** and **adrenomedullin**-binding
protein detn. in blood and tissues in diseases)
IT Antitumor agents
(stomach; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Gallbladder
(tumor inhibitors; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Vagina
(tumor, inhibitors; **adrenomedullin** and **adrenomedullin**
-binding protein detn. and antibodies utilization therein and treatment
of cancer and diabetes therewith)
IT Antitumor agents
(urethra; **adrenomedullin** and **adrenomedullin**-binding
protein detn. and antibodies utilization therein and treatment of
cancer and diabetes therewith)
IT Antitumor agents
(vaginal tumor inhibitors; **adrenomedullin** and
adrenomedullin-binding protein detn. and antibodies utilization
therein and treatment of cancer and diabetes therewith)
IT 154835-90-2, **Adrenomedullin**
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
unclassified); ANST (Analytical study); BIOL (Biological study); OCCU
(Occurrence)
(**adrenomedullin** and **adrenomedullin**-binding protein
detn. and antibodies utilization therein and treatment of cancer and
diabetes therewith)
IT 80295-65-4P, Complement factor H
RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,
unclassified); MFM (Metabolic formation); PRP (Properties); PUR

09921880

(Purification or recovery); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process)
(factor H detection as **adrenomedullin**-binding protein AMBP-1)
IT 540-72-7, Sodium thiocyanate
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(sodium thiocyanate as chaotropic agent in **adrenomedullin** detn.)

L3 ANSWER 5 OF 11 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2002134292 EMBASE
TI Editor's comment.
SO BJU International, (2001) 87/7 (i-ii).
ISSN: 1464-4096 CODEN: BJINFO
CY United Kingdom
DT Journal; Editorial
FS 016 Cancer
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
CT Medical Descriptors:
*nephrolithiasis: ET, etiology
*kidney cancer: DT, drug therapy
*prostate cancer
quality of life
side effect: SI, side effect
Peyronie disease: DT, drug therapy
drug efficacy
penis disease: CO, complication
retroperitoneum
laparoscopic surgery
pathology
urology
bladder exstrophy
data base
high risk population
urine
feces
risk factor
colon cancer
bladder cancer
retrospective study
cancer risk
age distribution
correlation function
ureteropelvic junction obstruction: ET, etiology
gene expression
hydronephrosis: ET, etiology
human
clinical trial
meta analysis
editorial
priority journal
Drug Descriptors:
*alpha interferon: AE, adverse drug reaction
*alpha interferon: DT, drug therapy
*alpha interferon: PD, pharmacology
*alpha interferon: SC, subcutaneous drug administration

09921880

*prostate specific antigen: EC, endogenous compound
endothelin 1: EC, endogenous compound
adrenomedullin: EC, endogenous compound
RN (**adrenomedullin**) 148498-78-6

L3 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS
AN 2000:911099 CAPLUS
DN 134:66714
TI **Adrenomedullin** for promoting passive elongation of **bladder** smooth muscle
IN Yanagita, Toshihiko
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000078338	A1	20001228	WO 2000-JP4166	20000623
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1205186	A1	20020515	EP 2000-940830	20000623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRAI JP 1999-177549 A 19990623
WO 2000-JP4166 W 20000623
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI **Adrenomedullin** for promoting passive elongation of **bladder** smooth muscle
AB This invention relates to compns. for promoting the passive elongation of **bladder** smooth muscle which contains **adrenomedullin**. These compns. are effective in relieving **urination** disorder. **Urination** disorder means urinary incontinence selected from the group consisting of impending urinary incontinence, reflex urinary incontinence and urinary incontinence with overflow. Also, a method for relieving **urination** disorder by using compns. contg. **adrenomedullin** and use of **adrenomedullin** for producing drugs for relieving **urination** disorder are also provided.
ST **adrenomedullin urination** disorder treatment; vesical smooth muscle elongation promoter **adrenomedullin**
IT Protein sequences
(**adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)
IT **Bladder**
(hyperreflexia; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)
IT **Bladder**
(incontinence; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)
IT **Bladder**
(obstruction; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)
IT Urinary tract
(urinary frequency; **adrenomedullin** for promoting passive

elongation of **bladder** smooth muscle to relieve **urination** disorders)

IT 154835-90-2, **Adrenomedullin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)

IT 148498-78-6, **Adrenomedullin** (human)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle to relieve **urination** disorders)

IT 152471-76-6 153268-10-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle)

IT 150680-26-5 151822-01-4 154338-24-6
RL: PRP (Properties)
(unclaimed protein sequence; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle)

IT 150680-28-7, **Adrenomedullin** (human clone pHAM-3)
RL: PRP (Properties)
(unclaimed sequence; **adrenomedullin** for promoting passive elongation of **bladder** smooth muscle)

L3 ANSWER 7 OF 11 MEDLINE DUPLICATE 1
AN 1999211857 MEDLINE
DN 99211857 PubMed ID: 10196022
TI Increased urinary levels of **adrenomedullin** in patients with cystitis.
AU Nishitani Y; Kubo A; Kaneko Y; Ono Y; Kurioka H; Kurooka K; Minamino N; Kangawa K; Okada K; Nonaka H; Dohi K
CS Department of Anesthesiology, Nara Medical University, Kashihara, Nara, Japan.
SO AMERICAN JOURNAL OF KIDNEY DISEASES, (1999 Apr) 33 (4) 772-7.
Journal code: 8110075. ISSN: 1523-6838.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199905
ED Entered STN: 19990525
Last Updated on STN: 20010521
Entered Medline: 19990510
TI Increased urinary levels of **adrenomedullin** in patients with cystitis.
AB In this study, we examined urinary levels of **adrenomedullin** (AM) in 18 healthy volunteers and 18 patients with cystitis. We also compared urinary levels of AM in 11 patients with cystitis before and after antibiotic treatment. Urinary AM concentrations were measured by a radioimmunoassay specific for human AM. Urinary AM levels in patients with cystitis were significantly elevated compared with those of healthy volunteers and correlated positively with the number of urine leukocytes. By antibiotic treatment, urinary AM levels significantly decreased as compared with before the treatment. By RNA blot analysis of AM transcript, we detected significant levels of AM mRNA in canine urinary **bladder** and ureter. Intravenous administration of

09921880

lipopolysaccharide elevated the AM mRNA level in the urinary **bladder**. These data suggest that infection and inflammation stimulate AM production in the urinary tract, which results in increased urinary AM levels in patients with cystitis. Based on these results, it is deduced that AM participates in the pathophysiology of cystitis, and its urinary level could be used as an index of the degree of cystitis.

CT Check Tags: Animal; Female; Human; Support, Non-U.S. Gov't
Adult
Antibiotics: TU, therapeutic use
Bladder: CH, chemistry
Cystitis: DT, drug therapy
*Cystitis: UR, urine
Dogs
Lipopolysaccharides: PD, pharmacology
Middle Age
Peptides: BL, blood
*Peptides: UR, urine
RNA, Messenger: AN, analysis
Radioimmunoassay
Vasodilator Agents: BL, blood
*Vasodilator Agents: UR, urine

RN **148498-78-6 (adrenomedullin)**

L3 ANSWER 8 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2

AN 1999:49197 BIOSIS

DN PREV199900049197

TI Increased urinary **adrenomedullin** excretion in children with urinary-tract infection.

AU Doetsch, Joerg; Haenze, Joerg; Knuefer, Verena; Steiss, Jens O.; Dittrich, Katalin; Seidel, Anke; Rascher, Wolfgang

CS Dep. Pediatr., Loschgestr. 15, D-91054 Erlangen Germany

SO Nephrology Dialysis Transplantation, (July, 1998) Vol. 13, No. 7, pp. 1686-1689.
ISSN: 0931-0509.

DT Article

LA English

TI Increased urinary **adrenomedullin** excretion in children with urinary-tract infection.

AB Background. **Adrenomedullin** (AM), a smooth-muscle relaxant peptide, is stimulated by cytokines and bacterial endotoxins. We hypothesized that urinary-tract infections may be associated with elevated urinary AM excretion. Methods. AM in urine was quantified in eleven children with urinary-tract infection and 11 age- and sex-matched controls by radioimmunoassay. RT-PCR was used to demonstrate local AM mRNA expression in the urinary tract. Results. In healthy controls but not in diseased children there was a significant correlation between AM and creatinine in urine ($r = 0.91$, $P < 0.001$). AM levels in children with urinary-tract infection were significantly higher than in controls (0.6 +- 0.41 vs 0.15 +- 0.14 ng/mumol creatinine; $P < 0.001$; (means +- SD)). There was a significant correlation between white cell count and AM in urine ($r = 0.78$, $P<0.001$). AM mRNA was expressed in renal tissue, renal pelvis, ureter, **bladder**, and urethra. Conclusion. The smooth-muscle relaxant peptide **adrenomedullin** that is synthesized in tissue of the human urinary tract is elevated in urine of patients with urinary-tract infections. A possible consequence might be the interference with the ureteral anti-reflux mechanisms.

IT Major Concepts
Infection; Urinary System (Chemical Coordination and Homeostasis)

IT Parts, Structures, & Systems of Organisms

09921880

urine: excretory system
IT Diseases
urinary-tract infection: bacterial disease, urologic disease
IT Chemicals & Biochemicals
adrenomedullin: urinary excretion; bacterial endotoxin; cytokines
RN 154835-90-2 (**ADRENOMEDULLIN**)

L3 ANSWER 9 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 3
AN 1997:112407 BIOSIS
DN PREV199799411610
TI The relaxant effect of **adrenomedullin** on particular smooth muscles despite a general expression of its mRNA in smooth muscle, endothelial and epithelial cells.
AU Nishimura, Junji; Seguchi, Hiroshi; Sakihara, Chie; Kureishi, Yasuko; Yoshimura, Hayashi; Kobayashi, Sei; Kanaide, Hideo (1)
CS (1) Div. Molecular Cardiol., Res. Inst. Angiocardiol., Fac. Med., Kyushu Univ., 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812 Japan
SO British Journal of Pharmacology, (1997) Vol. 120, No. 2, pp. 193-200. ISSN: 0007-1188.
DT Article
LA English
TI The relaxant effect of **adrenomedullin** on particular smooth muscles despite a general expression of its mRNA in smooth muscle, endothelial and epithelial cells.
AB 1. By use of the reverse transcription polymerase chain reaction (RT-PCR), we determined the expression of **adrenomedullin** (AM) mRNA in the various tissues of the pig. To evaluate the significance of the expression of AM mRNA, we also determined the effects of AM on the cytosolic Ca-2+ concentration ((Ca-2+)-i) and tension development of the porcine smooth muscle strips obtained from the coronary artery, pulmonary vein, trachea, ileum and urinary **bladder**. 2. AM mRNA was widely expressed in the porcine tissues examined, which included myocardium (left and right ventricle and right atrium), kidney, lung, endothelial cells (aorta and aortic valve), smooth muscles (aorta, main pulmonary artery, pulmonary vein, renal artery and vein, coronary artery, ileum, trachea and urinary **bladder**) and epithelial cells (trachea and urinary **bladder**). 3. AM induced a decrease in (Ca-2+)-i and tension of the coronary artery, but not the pulmonary vein. AM had no effects on either the (Ca-2+)-i or tension of the trachea and urinary **bladder** strips or on the tension development of strips of ileum. 4. These results indicated that AM has a role as an autocrine and/or paracrine regulator of the coronary arterial tone. AM probably does not have an important role in the regulation of the pulmonary venous, tracheal, ileac and urinary **bladder** smooth muscle tone, even though AM mRNA is expressed in these tissues; the functional significance of AM in these smooth muscles remains to be determined.
IT Miscellaneous Descriptors
ADRENOMEDULLIN; CALCIUM; CARDIOVASCULAR SYSTEM; CIRCULATORY SYSTEM; CONCENTRATION; CORONARY ARTERY; CYTOSOLIC; DIGESTIVE SYSTEM; ENDOTHELIAL CELL; EXCRETORY SYSTEM; EXPRESSION; ILEUM; LUNG; MESSENGER RNA; MUSCULAR SYSTEM; MYOCARDIUM; PHARMACOLOGY; PULMONARY VEIN; RELAXANT; RESPIRATORY SYSTEM; SMOOTH MUSCLES; TRACHEAL EPITHELIAL CELLS; URINARY **BLADDER** EPITHELIAL CELLS

L3 ANSWER 10 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1996:450158 BIOSIS
DN PREV199699172514
TI **Adrenomedullin** dose not relax the porcine urinary

•09921880

bladder smooth muscle despite the abundant expression of its mRNA.
AU Seguchi, Hiroshi; Nishimura, Junji; Kobayashi, Sei; Kanaide, Hideo
CS Div. Mol. Cardiol., Res. Inst. Angiocardiol., Fac. Med., Kyushu Univ., Fukuoka 812-82 Japan
SO Japanese Journal of Pharmacology, (1996) Vol. 71, No. SUPPL. 1, pp. 244P.
Meeting Info.: 69th Annual Meeting of the Japanese Pharmacological Society Nagasaki, Japan March 20-23, 1996
ISSN: 0021-5198.
DT Conference
LA English
TI **Adrenomedullin** dose not relax the porcine urinary **bladder** smooth muscle despite the abundant expression of its mRNA.
IT Miscellaneous Descriptors
ADRENOMEDULLIN; BIOCHEMISTRY AND BIOPHYSICS; EPITHELIAL CELL; EXPRESSION; MEETING ABSTRACT; MEETING POSTER; MESSENGER RNA; MRNA; MUSCULAR SYSTEM; URINARY **BLADDER** SMOOTH MUSCLE TONE; URINARY SYSTEM

L3 ANSWER 11 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1995:199595 BIOSIS
DN PREV199598213895
TI Presence and function of **adrenomedullin**, a novel vasorelaxant peptide, in the human urinary **bladder** detrusor muscle. An immunohistochemical and physiological study.
AU Takeda, Masayuki; Obara, Kenji; Tsutsui, Toshiki; Koizumi, Takako; Mizusawa, Takaki; Shimura, Hisanobu
CS Niigata Japan
SO Journal of Urology, (1995) Vol. 153, No. 4 SUPPL., pp. 461A.
Meeting Info.: Ninetieth Annual Meeting of the American Urological Association Las Vegas, Nevada, USA April 23-28, 1995
ISSN: 0022-5347.
DT Conference
LA English
TI Presence and function of **adrenomedullin**, a novel vasorelaxant peptide, in the human urinary **bladder** detrusor muscle. An immunohistochemical and physiological study.